NCT01231633

Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)

Comparative Study of Initial Ozurdex (Dexamethasone Implant) Versus Avastin (Bevacizumab) in the Treatment of Macular Edema Following Central Retinal Vein Occlusion (CRVO)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Long Island Vitreoretinal Consultants · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare visual improvement and total number of intraocular injections in eyes with macular edema following central retinal vein occlusion (CRVO)after initial treatment with Ozurdex (dexamethasone implant) or Avastin (bevacizumab).

Conditions

• Macular Edema
• Central Retinal Vein Occlusion

Interventions

Type	Name	Description
DRUG	Ozurdex	Ozurdex, 0.7mg dexamethasone
DRUG	Avastin	Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.

Timeline

• Start date: 2010-09-01
• Primary completion: 2014-09-01
• Completion: 2014-09-01
• First posted: 2010-11-01
• Last updated: 2018-04-03
• Results posted: 2018-04-03

Locations

4 sites across 1 country: United States